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ABSTRACT
Purpose Since 2016, the multicase- control study in 
Spain (MCC- Spain) has focused towards the identification 
of factors associated with cancer prognosis. Inception 
cohorts of patients with colorectal, breast and prostate 
cancers were assembled using the incident cases 
originally recruited.
Participants 2140 new cases of colorectal cancer, 
1732 of breast cancer and 1112 of prostate cancer were 
initially recruited in 12 Spanish provinces; all cancers 
were incident and pathologically confirmed. Follow- up was 
obtained for 2097 (98%), 1685 (97%) and 1055 (94.9%) 
patients, respectively.
Findings to date Information gathered at recruitment 
included sociodemographic factors, medical history, 
lifestyle and environmental exposures. Biological 
samples were obtained, and 80% of patients were 
genotyped using a commercial exome array. The 
follow- up was performed by (1) reviewing medical 
records; (2) interviewing the patients by phone on 
quality of life; and (3) verifying vital status and cause 
of death in the Spanish National Death Index. Ninety- 
seven per cent of recruited patients were successfully 
followed up in 2017 or 2018; patient- years of follow- 
up were 30 914. Most colorectal cancers (52%) 
were at clinical stage II or lower at recruitment; 819 
patients died in the follow- up and the 5- year survival 
was better for women (74.4%) than men (70.0%). 71% 
of breast cancers were diagnosed at stages I or II; 
206 women with breast cancer died in the follow- up 
and the 5- year survival was 90.7%. 49% of prostate 
cancers were diagnosed at stage II and 32% at stage 
III; 119 patients with prostate cancer died in the 
follow- up and the 5- year survival was 93.7%.
Future plans MCC- Spain has built three prospective 
cohorts on highly frequent cancers across Spain, 
allowing to investigate socioeconomic, clinical, lifestyle, 
environmental and genetic variables as putative 
prognosis factors determining survival of patients of 
the three cancers and the inter- relationship of these 
factors.
InTRoduCTIon
Tumour size, node infiltration, metastasis, 
histology, clinical stage and cancer subtype 
continue to be the main prognosis factors in 
patients with cancer in spite of the evolving 
first- line treatment.1–5 Little effort, however, 
has been paid to examine the impact on 
survival of patient factors, such as lifestyle, 
genetics or environmental, together with 
tumour features and treatment.
Large prospective cohort studies on cancer 
focus on identifying risk factors,6 while 
Strengths and limitations of this study
 ► 4837 incident cases of cancer (2097 colorectal; 
1685 breast; 1055 prostate) have been prospec-
tively followed up, accounting for more than 30 000 
patient- years and with only 153 patients (3%) lost 
to follow- up.
 ► The cohort covers a wide spectrum of the Spanish 
population including 23 hospitals across Spain.
 ► A major strength of this study is the amount of in-
formation gathered at diagnosis, including sociode-
mographic, lifestyle, nutrition, familial and personal 
medical history, reproductive history, use of drugs, 
sleep, genotyping, clinical and pathological charac-
teristics of the tumour, first- line treatment, side ef-
fects, health- related quality of life, and current vital 
status.
 ► Biological samples obtained at recruitment (tumour 
specimen, blood or saliva, toenail, hair and urine) 
will allow further investigations on metabolomics, 
epigenetics and exposure to chemicals such as 
metals.
 ► The multicentre characteristic of the study allows 
the evaluation of a wide geographical basis and 
increases the representativeness of the recruited 
sample, but it also may introduce heterogeneity in 
the information gathered and in treatment.
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clinical cohorts on cancer survival usually aim to analyse 
survival relationships with tumour properties, first- 
line treatment or patient characteristics. For instance, 
Lagendijk et al7 analysed data on 129 692 women with 
breast cancer from the Netherlands Cancer Registry to 
compare breast conserving therapy and mastectomy in 
subgroups according to age at diagnosis, stage, systemic 
therapy, comorbidity, oestrogen/progesterone recep-
tors and Her2 status. Cardwell et al8 linked the National 
Cancer Data Repository to the UK Clinical Practice 
Research Datalink and mortality data from the Office 
for National Statistics to investigate if statin use after 
colorectal cancer diagnosis was associated with better 
prognosis. Pettersson et al9 studied survival after pros-
tate cancer diagnosis in 121 392 Swedish men from the 
Prostate Cancer data Base Sweden V.3.0, where data were 
available on age, stage, grade, prostate- specific antigen 
(PSA) level, model of detection, comorbidity, educa-
tional level and primary treatment.9 It is noteworthy that 
these cohorts were based on cancer registries, where data 
availability is usually restricted to demographic variables 
(sometimes including educational level and deprivation), 
tumour characteristics and few data on comorbidities or 
healthy habits. A different approach has been the use of 
the Surveillance, Epidemiology and End Results (SEER) 
database to retrospectively analyse survivorship with 
breast cancer,10 colorectal cancer11 or prostate cancer,12 
but although the number of participants could be over 
100 000, available data are restricted to those recorded 
for the general purposes of the SEER programme, not 
specifically for studying survivorship with cancer.
The multicase- control study in Spain (MCC- Spain) 
includes three prospective cohorts of patients with cancer 
(colorectal, female breast and prostate) with the aim to 
investigate long- term survival factors, including cancer 
characteristics and treatment, but also genetics and 
other omics, lifestyle (physical activity, nutrition, sleep, 
toxic habits), occupational exposures (including night 
shift work), environmental factors such as living area 
conditions, and medical history, aiming to build integra-
tive prognosis models. This multidisciplinary study will 
provide a complete evaluation of the biological, clinical, 
environmental, lifestyle and socioeconomic factors deter-
mining survival of patients of the three cancers and of 
the inter- relationship of these factors. The following are 
the specific objectives for each cohort: For the colorectal 
cancer cohort: (1) to study the accomplishment of 
primary treatment with ESMO (European Society for 
Medical Oncology) and ASCO (American Society of 
Clinical Oncology) guidelines and factors associated 
with it; (2) to study factors associated with survivorship, 
response to treatment and toxicity due to chemotherapy 
using genetic, epidemiological and clinical- pathological 
variables; and (3) to validate those models via compar-
ison with Glasgow Prognostic Score predictions. For 
the breast cancer cohort: (1) to study whether first- line 
treatment accomplished the St Gallen International 
Expert Consensus recommendations; (2) to study factors 
associated with survivorship, response to treatment and 
toxicity due to chemotherapy using genetic, epidemio-
logical and clinical- pathological variables; and (3) to vali-
date those models via comparison with the Nottingham 
Prognostic Index and Adjuvant! For prostate cancer 
cohort: (1) to analyse the adequacy of initial treatment 
to the recommendations by the European Association of 
Urology and the National Institute for Health and Care 
Excellence; (2) to elaborate models on survivorship, risk 
of biochemical relapse, quality of life, response to primary 
treatment and toxicity to chemotherapy/brachytherapy; 
and (3) to validate survivorship and risk of biochemical 
relapse models via comparison with Han and Kattan 
nomograms. In this article, we report the study design, 
the main description of all three cohorts and the prelimi-
nary results on survival.
CohoRT deSCRIPTIon And meThodS
The MCC- Spain began as a case–control study in 2008, 
started by the Consortium for Biomedical Research in 
Epidemiology and Public Health (CIBERESP), on both 
genetic and environmental exposures associated with 
colorectal, female breast, prostate and gastric cancers 
and chronic lymphocytic leukaemia. Its design has been 
published elsewhere13; it recruited 10 183 incident cases 
and controls between 2008 and 2013 in 12 Spanish prov-
inces (Asturias, Barcelona, Cantabria, Girona, Granada, 
Gipuzkoa, Huelva, León, Madrid, Murcia, Navarra and 
Valencia). Using the incident cases originally recruited 
between 2008 and 2013, and given that in 2016 the MCC- 
Spain has turned towards the identification of factors 
associated with cancer prognosis, inception cohorts on 
colorectal, breast and prostate cancers have been assem-
bled, enrolling the patients for a prospective follow- up 
carried out in 2017–2018. From here on, we only refer 
to the recruited cases of colorectal (2140 cases), breast 
(1738 cases) and prostate (1112 cases) cancers; their 
distribution by province and hospital appears in online 
supplementary table 1 and the flow chart appears in 
figure 1.
Patient recruitment and public involvement statement
Patients recruited were between 20 and 85 years old, had 
resided in the catchment area for at least 6 months before 
the recruitment and were able to answer the epidemio-
logical questionnaire, and had incident colorectal, breast 
or prostate cancer. For the recruitment, study personnel 
contacted newly diagnosed cancer cases in the 21 collabo-
rating hospitals. Cases were identified as soon as possible 
after the diagnosis; only histologically confirmed incident 
cases were included.
Participants are being informed on the project’s main 
results via flyers. There is no other patient involvement.
Information at recruitment and biological samples
The information obtained and its timing is summarised 
in table 1.
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Figure 1 Flow chart of the participants in the MCC- Spain study. MCC- Spain, multicase- control study in Spain.
Information about sociodemographic, personal and 
familial medical history, use of drugs, reproductive 
history, physical activity, and environmental and occu-
pational exposures was gathered using a standardised 
questionnaire14 administered by trained personnel in a 
face- to- face interview. Diet information in the year before 
diagnosis was obtained using a validated semiquantita-
tive frequency- food questionnaire15 filled by the partic-
ipants. Both questionnaires can be found at http://
www. mccspain. org. Biological samples were obtained, 
including peripheral blood or saliva (from 92% of breast 
cancer cases, 95% of colorectal cancer cases and 97% of 
prostate cancer cases), toenail and hair (from 77% and 
81% of participants, respectively), urine or tumour biop-
sies. Regarding peripheral blood, 27 mL was aliquoted 
in whole blood, plasma, serum and cellular fraction for 
DNA extraction and stored at −80°C. Saliva was collected 
from people unable to donate a blood sample.
Genotyping
From 80% of the participants, a genotype of exome was 
made using the Illumina Infinium HumanExome. In 
addition to the about 250 000 exome variants included 
in the original beadchip, 6000 SNPs previously found in 
GWAS (Genome- wide Association Study) or localised in 
metabolic pathways of interest were added on MCC- Spain 
researchers’ request. MCC- Spain has recently obtained 
funding for carrying out a GWAS with all the participants 
and to launch an analysis on circulant microRNA in 
patients with breast cancer.
Initial clinical information
Trained personnel reviewed the medical records in 
order to collect information on pathology characteristics, 
tumour extension, clinical data, first- line treatment and 
recurrence. For colorectal cancer cases, we documented 
the first biopsy, tumour location, surgical piece dimen-
sions, histological type according to the International Clas-
sification of Diseases for Oncology, Third Edition, tumour, 
node, metastases (TNM) status, carcinoembryonic antigen 
levels, and first- line treatment (surgery extension, if done; 
neoadjuvant, adjuvant or palliative chemotherapy or radio-
therapy). For breast cancers, we obtained information on 
tumour location, differentiation’s degree, immunohisto-
chemical characteristics (hormonal receptors, Erb- B2), 
TNM status and first- line treatment (mastectomy/conserva-
tive surgery; neoadjuvant, adjuvant or palliative hormono-
therapy, chemotherapy or radiotherapy; target- directed 
therapy such as trastuzumab). For prostate cancer cases, we 
gathered information on tumour location, Gleason score, 
D’Amico classification, TNM status, PSA levels and first- 
line treatment (none, surgery, hormonotherapy, chemo-
therapy or radiotherapy, including, when appropriate, the 
purpose of therapy—neoadjuvant, adjuvant or palliative). 
TNM status for all three tumours was classified according 
to TNM sixth edition.
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Table 1 Information obtained in the MCC- Spain
Phase Measurements
Phase I: 
recruitment
2008–
2013
Contact with newly diagnosed cancer cases.
Trained personnel perform a structured computerised epidemiological questionnaire in a 
face- to- face interview to obtain the following information: sociodemographic, personal and 
familial medical history, use of drugs, reproductive history, physical activity, environmental and 
occupational exposures.
A validated semiquantitative frequency- food questionnaire is self- completed to obtain diet 
information.
Biological samples are obtained: peripheral blood or saliva, toenail, hair, urine, tumour biopsies.
A genotype of exome is made using the Illumina Infinium HumanExome.
Medical records review by trained personnel to obtain the following: pathology characteristics, 
tumour extension, clinical data, first- line treatment, recurrence.
For colorectal cancer cases First biopsy, surgical piece dimensions, histological type, 
carcinoembryonic antigen levels.
For breast cancers cases Differentiation’s degree, immunohistochemical 
characteristics.
For prostate cancer cases Gleason score, D’Amico classification, PSA levels.
Phase II: follow- 
up
2017–
2018
Medical records review by trained personnel to obtain the following:
For colorectal cancer cases TNM status at recruitment, first- line treatment, surgical 
margins, patient status after first- line treatment, 
appearance of second primary tumour, current patient’s 
vital status.
For breast cancers cases Histological grade at diagnosis, Nottingham index, 
complete clinical/pathological remission, grade of response 
to treatment, relapse, second primary tumour, current 
patient’s vital status.
For prostate cancer cases PSA concentration, Gleason grade and biopsy 
characteristics at diagnosis, pathological characteristics of 
the surgical specimen, first- line treatment, clinical response 
to first- line treatment, second primary tumour, current 
patient’s vital status.
Consult in the IND to realise the vital status of patients.
Contact by phone to complete specific quality of life questionnaires.
For colorectal cancer cases SF-12, FACT- Colorectal Symptom Index.
For breast cancer cases SF-12, FACT/NCCN Breast Symptom Index.
For prostate cancer cases SF-12, Charlson Comorbidity Index, FACT- P questionnaire, 
International Prostate Symptom Score.
SF-12: 12- Item Short Form Survey; FACT: Functional Assessment of Cancer Therapy (P for prostate, B for breast cancer); FACT/NCCN: 
Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network.
IND, Índice Nacional de Defunciones; MCC- Spain, multicase- control study in Spain; PSA, prostate- specific antigen; TNM, tumour, node, 
metastases.
Follow-up information
Follow- up was carried out between 2017 and 2018 by 
reviewing medical records. For patients with colorectal 
cancer, we collected data on TNM status at recruitment, 
first- line treatment, surgical margins, patient status after 
first- line treatment (free of disease, partial response, 
progression, relapse or stable disease), appearance of 
second primary tumour and current patient’s vital status. 
For patients with breast cancer, we gathered information 
on histological grade at diagnosis, Nottingham index, 
complete clinical/pathological remission, grade of 
response to treatment (according to the Miller and Payne 
system or similar classifications), relapse, second primary 
tumour and current patient’s vital status. For patients 
with prostate cancer, the information assembled included 
PSA concentration, Gleason grade and biopsy charac-
teristics at diagnosis, pathological characteristics of the 
surgical specimen, first- line treatment, clinical response 
to first- line treatment (stable disease/progression or 
relapse/unknown), chemical relapses, relapse clinical 
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characteristics (local/metastatic and its location), second 
primary tumour, and current patient’s vital status. Some 
of these data were obtained in order to double- check the 
clinical information collected at recruitment.
The National Death Index (Índice Nacional de Defun-
ciones (IND)) was consulted to realise the vital status of 
patients whose last contact with the hospital had occurred 
3 or more months before our revision of his/her medical 
record. The IND is a nationwide database supported by 
the Spanish Ministry of Health; it is intended to allow the 
researchers to establish the vital status of patients under 
study.16
Patients alive at follow- up were contacted by phone and 
asked to complete specific quality of life questionnaires: 
SF-1217 (12- Items Short Form Survey; colorectal, breast 
and prostate cancers), FACT- Colorectal Symptom Index18 
(Functional Assessment of Cancer Therapy; colorectal 
cancer), FACT/NCCN (National Comprehensive Cancer 
Network) Breast Symptom Index19 (breast cancer), and 
for prostate cancer the Charlson Comorbidity Index,20 
the FACT- P questionnaire (Functional Assessment of 
Cancer Therapy Prostate)21 and the International Pros-
tate Symptom Score.22
The number of patients with follow- up is 2097 for 
colorectal, 1685 for breast and 1055 for prostate cancer 
cohorts. This gives a 91% statistical power for colorectal 
cancer to detect an HR ≥1.2; an 83% statistical power 
for breast cancer to detect the same HR; and an 80% 
statistical power for prostate cancer to detect an HR 
≥1.25 (assuming 20% exposed patients and 75%, 90% 
and 85% survival probability in the non- exposed group, 
respectively).
Statistical analysis
For preliminary results shown in this paper, data are 
described using absolute frequencies with percentages 
and means with SD. Patients who died by any cause 
before the end of follow- up were classified as events and 
censored otherwise. Time of follow- up was the difference 
between date of diagnosis and date of death or date of 
last contact with the hospital or the researchers. Survival 
probabilities were obtained using unadjusted Kaplan- 
Meier estimators. Further analyses should deal with 
confounding and modifiers using multivariate regression 
models (eg, Cox or Weibull regression). Initial treatment 
could be related with both basal factors and survivorship, 
eventually leading to confounding by indication; it would 
be controlled using propensity scores.
ethics
The protocol of MCC- Spain was approved by the ethics 
committees of the participating institutions.13 At recruit-
ment, all participants were informed about the study 
objectives and signed an informed consent, which also 
included the authorisation for following up the patient 
via medical records or phone calls. Only participants 
agreeing to being followed up were included in the 
inception cohorts. Confidentiality of data is secured by 
removing personal identifiers in the data sets. The data-
base was registered in the Spanish Agency for Data Protec-
tion (number 2102672171).
FIndInGS To dATe
The MCC- Spain has provided results on the effects of 
different risk factors. For instance, night shift work 
increased the risk of more aggressive prostate cancers,23 
although this excess risk almost disappeared 20 years 
after last exposure24; long- term consumption of calcium 
channel blockers was associated with higher breast 
cancer risk in overweight women25; adherence to the 
Western dietary patterns increased breast cancer risk 
in both premenopausal and postmenopausal women26; 
first validation in a European population of a risk model 
for breast cancer developed in American women using 
both modifiable and non- modifiable risk factors as 
well as 92 genetic variants27; use of environmental and 
genetic factors to elaborate a model to stratify the risk of 
colorectal cancer28; and adherence to the World Cancer 
Research Fund/American Institute for Cancer Research 
nutrition- based guidelines was associated with lower 
risk of colorectal and breast cancers, but not of pros-
tate cancer.29 A complete list of published results from 
MCC- Spain appears in online supplementary table 2 and 
supplementary reference list.
Initial results of the follow- up are shown in this work. 
Table 2 displays the main characteristics of the patients; 
table 3 details specific information of each tumour; and 
table 4 describes first- line treatment.
Colorectal cancer
Out of 2140 patients with colorectal cancer, 2097 (98%) 
have been followed. They were 67±10.9 years old on 
average at recruitment, and 1334 (63.4%) were men. 
The first case was recruited on 18 March 2007 and the 
follow- up was closed on 23 August 2018, accounting for 
12 813.8 person- years of follow- up. During this period, 
819 (39.1%) cases died. Linearised mortality rate was 6.4 
per 100 patient- years (95% CI 6.0 to 6.8) (table 2).
Most cases (1882, 90%) were adenocarcinoma, and 
the most frequent location was rectum- sigma (37.7%) 
and the less frequent right colon (27%). Of the patients, 
52% were at clinical stage II or lower, and in 110 patients 
(5.3%) we could not establish the clinical stage. Of the 
cancers, 52.5% were moderately differentiated (grade II) 
and 24.8% well differentiated (grade I) (table 3).
Surgery was carried out in 1999 patients with colorectal 
cancer, and it was for palliative purposes in 127 patients 
(6.1%). There were 169 patients who were treated via 
endoscopy, reaching complete resection in 107 of them. 
There were 1518 (72.4%) patients who received chemo-
therapy, and most of them (1451) were for adjuvant or 
neoadjuvant purposes; 488 (23.2%) received radio-
therapy (401 neoadjuvant, 82 adjuvant and only 5 palli-
ative) (table 4).
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Table 2 Main characteristics of the followed patients
Variable Category Colorectal cancer (n=2097)
Breast cancer
(n=1685)
Prostate cancer
(n=1055)
Age, mean (±SD) 66.98 (±10.85) 56.5 (±12.6) 65.86 (±7.38)
Gender Female 763 (36.39%) 1685 (100%) –
Male 1334 (63.61%) – 1055 (100%)
Postmenopausal Yes – 1095 (65.0%) –
No – 589 (35.0%) –
Missing – 1 (0.1%) –
Histology
(specific types in each tumour)
Adenocarcinoma: 1882 (89.75%) Ductal: 1276 
(75.7%)
Adenocarcinoma 
(acinar): 1053 (99.91%)
Mucinous adenocarcinoma: 125 (5.96%) Lobular :110 
(6.5%)
Others: 2 (0.09%)
Signet ring cells adenocarcinoma: 12 (0.57%) Paget disease: 
19 (1.1%)
–
Others: 4 (0.19%) Others: 280 
(16.6%)
–
Unknown: 74 (3.53%) – –
Tumour size T0 98 (4.67%) 23 (1.4%) –
T1 125 (5.96%) 861 (51.1%) 227 (21.52%)
T2 283 (13.49%) 424 (25.2%) 521 (49.38%)
T3 1172 (55.89%) 73 (4.3%) 98 (9.29%)
T4 319 (15.21%) 39 (2.3%) 8 (0.76%)
Tis – 109 (6.5%) –
Missing 100 (4.77%) 156 (9.3%) 196 (18.58%)
Not evaluable – – 5 (0.47%)
Node infiltration N0 1193 (56.89%) 877 (52.0%) 271 (25.69%)
N1 515 (24.56%) 441 (26.2%) 9 (0.85%)
N2 286 (13.64%) 186 (11.0%) –
N3 – 5 (0.3%) –
Missing 103 (4.91%) 176 (10.4%) 224 (21.23%)
Not evaluable – – 551 (52.23%)
Metastasis No 1721 (82.07%) 1376 (81.7%) 532 (50.43%)
Yes 330 (15.74%) 41 (2.4%) 17 (1.61%)
Missing 46 (2.19%) 268 (15.9%) 215 (20.38%)
Not evaluable – – 291 (27.58%)
Clinical stage 0 77 (3.67%) – –
I 338 (16.12%) 702 (41.7%) 367 (34.79%)
II 673 (32.09%) 479 (28.4%) 496 (47.01%)
III 569 (27.13%) 179 (10.6%) 132 (12.51%)
IV 330 (15.74%) 41 (2.4%) 17 (1.61%)
Missing 110 (5.25%) 284 (16.9%) 43 (4.08%)
The 5- year survival probability estimated via Kaplan- 
Meier was 71.6% (95% CI 69.6 to 73.5) (figure 2A). 
Survival was higher in women (74.4%, 95% CI 71.0 to 
77.2) than in men (70.0%, 95% CI 67.5 to 72.4) (p<0.001) 
(figure 2B). The 5- year survival probability was 85.2% 
(81.0–88.6) in patients diagnosed with stage I, 84.0% 
(81.0–86.6) with stage II, 73.4% (69.6–76.9) with stage III 
and 27.6% (22.9–32.5) with stage IV (figure 3A).
Breast cancer
The maximum span for breast cancer follow- up was 9.5 
years (from 13 July 2007 to 22 March 2017). Follow- up 
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Table 4 First- line treatment
Treatment Category Colorectal cancer Breast cancer Prostate cancer
None (active surveillance) – – 38 (3.6%)
Surgery Total: 1999 (95.3%) Conservative:
1231 (73.1%)
Prostatectomy: 639 (61.4%)
Resection: 1800 (85.8%)
Palliative: 127 (6.1%) Mastectomy:
454 (26.9%)No resection: 61 (2.9%)
Others: 11 (0.5%)
Chemotherapy Neoadjuvant 427 (20.4%) 200 (11.9%) 1 (0.1%)
Adjuvant 1024 (48.8%) 664 (39.4%) 1 (0.1%)
Palliative 67 (3.2%) 25 (1.5%) 7 (0.7%)
Radiotherapy Neoadjuvant 401 (19.1%) 5 (0.3%) 227 (21.5%)
Adjuvant 82 (3.9%) 1132 (67.2%) 36 (3.4%)
Palliative 5 (0.2%) 21 (1.2%) 2 (0.2%)
Endocrine therapy Yes – 1023 (60.7%) Adjuvant to surgery: 19 (1.8%)
Adjuvant to radiotherapy: 99 
(9.4%)
Neoadjuvant: 102 (9.7%)
Palliative: 69 (6.5%)
No – 662 (39.3%) 689 (65.3%)
Others (specify for each 
tumour)
Endoscopy Complete resection: 107 (5.1%) – –
Non- complete resection: 62 
(3.0%)
Her2- targeted therapy – 152 (9.0%) –
Cryotherapy – – 21 (2.0%)
Transurethral resection – – 4 (0.4%)
was obtained for 1685 out of 1738 patients with breast 
cancer (97%), adding 10 931 person- years; 206 patients 
died in the follow- up. The linearised mortality rate was 
1.9 per 100 patient- years (95% CI 1.6 to 2.2).
Women with breast cancer were 56.5±12.6 years old on 
average at recruitment, and 65% were postmenopausal. 
The most usual type of tumour was ductal (75.7%), 
followed by lobular (6.5%). Most breast cancers were 
diagnosed at early stages (71% at stages I or II) and 
only 41 (2.4%) had metastasised at the time of diagnosis 
(table 2). Of the cancers, 83% were oestrogen receptor- 
positive, 73.4% progesterone receptor- positive and 
17.4% Her2- positive. Regarding intrinsic subtypes, 997 
(59.2%) could be classified as luminal A, 331 (19.6%) as 
luminal B, 81 (4.8%) as Her2 and 130 (7.7%) as basal- 
like. According to grade of differentiation, moderately 
differentiated accounted for 30.9% of breast cancers, and 
well differentiated and bad differentiated accounted for 
about 20% of cancers each. Grade could not be obtained 
from medical records in 481 patients (28.5%) (table 3).
Conservative surgery was performed in 1231 (73.1%) 
patients and mastectomy in the remaining 454 (26.9%). 
Adjuvant or neoadjuvant chemotherapy was adminis-
tered to 50.3% of patients, while radiotherapy was used 
in 1158 women (68.7%), endocrine therapy was used in 
1023 women (60.7%) and Her2- targeted therapy in 152 
patients (9.0%) (table 4). Kaplan- Meier 5- year survival 
with breast cancer was 90.7% (95% CI 89.2 to 92.0) 
(figure 2C). Women diagnosed with stage I had 97% 
(95.5–98.1) 5- year survival probability, 91.9% (89.1–94.1) 
at stage II, 84.1% (77.8–88.7) at stage III and 38.5% 
(18.6–58.2) at stage IV (figure 3B).
Prostate cancer
A total of 1112 men with prostate cancer were recruited 
and 1055 (94.9%) have been followed up. The first 
patient was included on 26 January 2008 and the end of 
follow- up was on 13 July 2018, adding 7169.6 person- years 
of follow- up. Patients were 65.9 years old on average at 
recruitment. There were 119 patients who died in the 
follow- up, making the linearised mortality rate 1.7 per 
100 patient- years (95% CI 1.4 to 2.0).
Almost all prostate cancers (99.9%) were adenocar-
cinoma; 496 (47%) were diagnosed at stage II and 132 
(12.5%) at stage III (table 2). The level of PSA gives an 
average of 11.5±16.3 ng/mL. Considering the Gleason 
score, 42.6% of prostate cancers were well differenti-
ated (Gleason grade=1, ie, Gleason score=6), 28.3% 
were at Gleason grade 2 (Gleason score=3+4), and only 
14.0% were bad differentiated (Gleason grade 4 or 5, 
ie, Gleason score ≥8). Gleason grade could not be estab-
lished in 17.4% of patients. D’Amico classification system 
results in 31.4% of patients with low- risk cancer, 41.1% 
intermediate- risk and 27.4% high- risk cancer (table 3).
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Figure 2 Kaplan- Meier survival estimates for colorectal cancer (A), colorectal cancer by sex (B), breast cancer (C) and prostate 
cancer (D).
Thirty- eight patients with prostate cancer were not 
treated medically at the beginning, being followed by 
active surveillance. Prostatectomy was performed in 
61.4% cases, radiotherapy in 265 patients (25.1%) and 
endocrine therapy in 289 patients (27.4%). A small 
number of patients were treated via transurethral resec-
tion, cryotherapy or chemotherapy (table 4). The 5- year 
survival probability by Kaplan- Meier was 93.7% (95% CI 
92.0 to 95.1) (figure 2D). Survival probability 5 years after 
being diagnosed was 94.5% (88.1–97.5) for patients at 
stage I, 95.6% (93.3–97.2) at stage II, 92.4% (88.5–95.0) 
at stage III and 70.5% (42.8–88.6) at stage IV (figure 3C).
STRenGThS And lImITATIonS
In this article, we have described how three prospec-
tive cohorts on colorectal, breast and prostate cancers 
have been assembled from patients originally recruited 
for a case–control study, with 97% patients followed 
up and accounting for more than 30 000 person- years. 
This is a main achievement of a network settled within 
the CIBERESP in 12 Spanish provinces. The study is 
population- based and included only incident cancers. The 
amount of detailed information recorded as well as the 
availability of biological samples at recruitment will allow 
the identification of genetics, environmental, lifestyle 
and clinical prognosis factors in three frequent cancers 
in Spain. In this regard, a remarkable feature of the study 
is the feasibility of studying cancer risk factors as putative 
prognosis factors. For example, risk factors already anal-
ysed in the case–control phase were diet, circadian cycle 
disruption, some drugs, endocrine disruptors, artificial 
light or proximity to green spaces; information regarding 
these risk factors was recorded at recruitment and is avail-
able for a prognosis factor analysis in the follow- up (see 
online supplementary material for a complete reference 
list of MCC- Spain articles).
Obtaining information on personal history, occupa-
tional exposures, diet, physical exercise or other lifestyle 
components is somewhat subjective as both patients and 
interviewers could be prone to be influenced by their feel-
ings or beliefs about the hypotheses under study, eventu-
ally leading to differential misclassification bias. This could 
hardly have occurred in this study. First, patients were 
not aware of the hypotheses. Second, interviewers were 
familiar with the case–control study, not with the cohort 
design as it was decided later; therefore, if interviewers or 
patients have introduced some misclassification, it could 
probably have been non- differential, eventually leading 
to bias towards the null,30 which would make more robust 
the positive findings in this cohort study.
This study also has some weaknesses. First, multi-
centre studies are double- edged; they are needed in 
order to include many patients, but they could introduce 
heterogeneity in both the information gathered and 
the way patients are treated. In this regard, the analysis 
of prognosis factors should be adjusted for the hospital 
of recruitment. Second, 113 participating patients have 
been lost (43 with colorectal cancer, 53 with breast cancer 
and 57 with prostate cancer). We have tried to mini-
mise it by searching information in three ways: medical 
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Figure 3 Kaplan- Meier estimates by stage at diagnosis for 
colorectal cancer (A), breast cancer (B) and prostate cancer 
(C).
records, phone calls and IND; however, we cannot rule 
out that some patients without follow- up could have died. 
It is noteworthy that, due to the small number of patients 
without follow- up, the maximum bias it could introduce in 
our survival estimates is 2% for colorectal cancer, 3% for 
breast cancer and 5% for prostate cancer. Third, we have 
not obtained information on lifestyle changes after diag-
nosis, which limits lifestyle analysis to habits before cancer 
appearance. Fourth, the number of patients included in 
our cohorts is small compared with those based on cancer 
registries, limiting the analysis of subgroups.
Summarising, the MCC- Spain study has assembled three 
cohorts with about 4700 patients with cancer accounting 
for 30 000 patient- years of follow- up, with only 3% patient 
withdrawals. The information gathered at recruitment 
will allow to prospectively investigate clinical, lifestyle, 
environmental and genetic variables as prognosis factors 
in colorectal, breast and prostate cancers in Spain.
Samples
Biological samples were stored at the biobanks supported 
by Instituto de Salud Carlos III- FEDER: Parc de Salut MAR 
Biobank (MARBiobanc) (RD09/0076/00036), ‘Biobanco 
La Fe’ (RD 09 0076/00021) and FISABIO Biobank (RD09 
0076/00058), and also at the Public Health Laboratory 
from Gipuzkoa, the Basque Biobank, the ICOBIOBANC 
(sponsored by the Catalan Institute of Oncology), the 
IUOPA Biobank from the University of Oviedo and the 
ISCIII Biobank.
Collaborators
MCC- Spain already participates in international consor-
tiums such as Genetics and Epidemiology of Colorectal 
Cancer Consortium (GECCO; https://www. fredhutch. 
org/ en/ labs/ phs/ projects/ cancer- prevention/ projects/ 
gecco. html), Breast Cancer Association Consortium 
(BCAC; http:// bcac. ccge. medschl. cam. ac. uk/) and Pros-
tate Cancer Association Group to Investigate Cancer Asso-
ciated Alterations in the Genome (PRACTICAL; http:// 
practical. icr. ac. uk/ blog/), where MCC- Spain would 
contribute to study interactions among the putative prog-
nosis factors in vast population samples.
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